Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((s)-oxetan-2-yl) methyl)-1h-benzo [d] imidazol-6-carboxylic acid, 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt

The present invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((S)-oxetan-2-yl) methyl)-1H-benzo [d] imidazol-6-carboxylic acid, a 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt, for example, a salt of a compound represented by formula (I). A crystalline form (e.g., Form 2 or Form 3) or an amorphous form of a hydrate (e.g., a monohydrate); and pharmaceutical compositions and their use in the treatment of diseases, conditions or disorders modulated by GLP-1R in mammals, such as humans. 本发明提供了2-((4-((S)-2-(5-氯吡啶-2-基)-2-甲基苯并[d][1,3]二氧杂环戊烯-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-苯并[d]咪唑-6-甲酸,1,3-二羟基-2-(羟基甲基)丙烷-2-胺盐的固体形式，例如，水合物(例如一水合物)结晶形式(例如形式2或形式3)或无定形形式；以及药物组合物，及其在哺乳动物诸如人中治疗由GLP-1R调节的疾病、病症或障碍的用途。